Medical Oncologist
Deciding on radiotherapy
Genomic testing in DCIS: is it useful?
Sometimes, and for a different question than in invasive cancer. Chemotherapy is not given for DCIS, so the test is not about that. It estimates whether radiotherapy after surgery is worth having, or whether it can safely be left out. This page explains when that question is genuinely open and where the evidence behind the test is still thin.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
The short answer
Is a genomic test useful if I have DCIS?
Sometimes, and for a different question than in invasive cancer. In DCIS the test is not about chemotherapy, which is not given for DCIS. It is about whether radiotherapy after surgery is worth having, or whether it can safely be left out.
Why that question exists at all
DCIS is cancer cells still held inside the milk ducts. Removed with a clear edge, many cases would never have caused harm. Radiotherapy lowers the chance of anything returning in that breast, but it is weeks of appointments with its own effects, and not everyone needs it.
What the test does
It reads genes in the removed DCIS tissue and estimates the chance of something returning in that breast if radiotherapy is not given. A low result supports leaving it out. A higher one supports having it.
This is a different test and a different question from the recurrence score used in invasive breast cancer.The vocabulary
The words used in this decision
- DCIS
- Ductal carcinoma in situ. Cancer cells inside the milk ducts that have not broken out into the surrounding breast tissue.
- Local recurrence
- Something returning in the same breast. This is what the test estimates the chance of, and it is the main risk in DCIS.
- Invasive recurrence
- Something returning that has broken out of the ducts. This is the outcome that matters most and is the one worth asking about specifically.
- Breast conservation
- Removing the DCIS and keeping the breast. Radiotherapy is usually discussed alongside it.
- Margin
- The rim of normal tissue around what was removed. A generous clear margin is part of what makes leaving out radiotherapy reasonable.
- Endocrine therapy
- Hormone tablets, sometimes offered after DCIS surgery to lower the chance of anything returning in either breast.
When it helps
When the test is worth considering
As with every genomic test, it earns its cost only when the decision is genuinely open.
Small, low grade DCIS, widely cleared
This is the classic situation where leaving out radiotherapy is already being discussed, and a low result can support that conversation with something more than intuition.
When you want to avoid radiotherapy
Distance from the centre, work, caring for family or other health conditions all make weeks of daily appointments hard. Those are legitimate reasons to want the question answered properly.
Say so plainly rather than simply not attending.When your team is genuinely undecided
If your surgeon and radiation oncologist differ, the test can give the discussion something concrete. If they agree, it will usually just confirm what they told you.
Not when the answer is already clear
Extensive, high grade DCIS with a narrow margin, or a young woman with a large area removed. Radiotherapy is usually advised in those situations and the test will not change it.
Ask first
- Is leaving out radiotherapy on the table
- Would a low result change your advice
- What does the test cost all in
Not sure whether this applies to you?
Ask an oncologistTalk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Side by side
Genomic testing in DCIS and in invasive cancer
In DCIS
In invasive breast cancer
Answers whether radiotherapy can be left out
Answers whether chemotherapy is worth adding
Estimates the chance of something returning in the same breast
Estimates the chance of the cancer returning elsewhere in the body
Used less often, and by fewer centres
Well established and widely used
Evidence base is smaller and still developing
Backed by large studies with years of follow-up
Chemotherapy is not part of the conversation
Chemotherapy is the whole conversation
Being straight with you
Where the evidence is thinner
Genomic testing in DCIS is less established than in invasive breast cancer. The studies behind it are smaller, the follow-up is shorter and guidelines are more cautious about it. That is worth knowing before you pay for one.
What the result is actually estimating
Most of what the test predicts is the chance of anything returning in that breast, including further DCIS. Ask specifically what it says about the chance of an invasive recurrence, because that is the outcome that matters most and it is not always the headline figure.
Leaving out radiotherapy is not the same as doing nothing
If radiotherapy is left out, hormone tablets are often offered instead, and follow-up imaging matters more. Make sure you know the whole alternative plan rather than only the part you are avoiding.
What this page cannot tell you
It cannot tell you whether to have radiotherapy. What it can do is get you to the right conversation: ask whether leaving it out is genuinely on the table for your DCIS, and only then ask whether a test would help decide. In that order, the question is a good one.
Ask about the practical burden too
Radiotherapy means daily visits over several weeks, and for a family travelling in from a district that is the part nobody costs properly. Raise it openly. Shorter schedules exist for some situations, and a team that knows travel is the obstacle can often plan around it rather than watching you drop out half way through.
Commonly believed
What people assume about DCIS and testing
DCIS is not really cancer, so no treatment is needed.
It is cancer that has not broken out of the ducts. Left in place, some of it becomes invasive over time. Removing it with a clear edge is the point of the surgery, and the debate is only about what should be added afterwards.
A genomic test will tell me I do not need radiotherapy.
It may say the opposite. These tests return higher results often enough that going in expecting permission to skip treatment is a poor basis for paying. Ask what you will do with either answer before you order it.
The same test used for invasive cancer applies here.
It does not. The DCIS test is a different one answering a different question. If you are being quoted for a recurrence score for DCIS, check carefully which test is actually being proposed.
Skipping radiotherapy means the risk goes away.
It means accepting a somewhat higher chance of something returning in that breast, in exchange for avoiding weeks of treatment. That can be a sensible trade, and it should be made with the actual figures in front of you.
Questions we are asked
Common questions about genomic testing in DCIS
Do I need chemotherapy for DCIS?
No. Chemotherapy is not given for DCIS, because cells confined to the ducts cannot travel elsewhere in the body. The treatments in question are surgery, radiotherapy and sometimes hormone tablets.
Can I refuse radiotherapy after DCIS surgery?
You can, and for some women with small, low grade, widely cleared DCIS it is a reasonable option that teams offer anyway. Ask for the figures both ways and ask what the follow-up plan would be if you decline.
Is the DCIS test available in India?
Availability varies and it is used by far fewer centres than the invasive-cancer tests. Ask your hospital whether they can arrange it, what it costs all in, and how long the result would take.
Will hormone tablets be offered instead?
Often, if your DCIS is hormone receptor positive. They lower the chance of something returning in either breast. They are a different treatment from radiotherapy rather than a direct substitute, so ask what each contributes.
Does the test predict whether it will become invasive?
It gives an estimate that includes invasive recurrence, but it is not a direct forecast for you. Ask your oncologist to point out the invasive recurrence figure specifically rather than reading only the overall number.
Is my margin more important than the test?
The margin is one of the strongest factors in this decision, along with the grade and how much DCIS there was. A test adds to that picture rather than replacing it, which is why it is only useful in borderline cases.
What if I had a mastectomy for DCIS?
Radiotherapy is usually not needed after the whole breast is removed for DCIS, so the question the test answers does not arise. Your follow-up will focus on the other breast and on the chest wall.
Should I get a second opinion on this decision?
It is reasonable, because opinions on radiotherapy after DCIS genuinely differ between careful doctors. Take the pathology report with the grade, the size and the margin, since those three things drive most of the disagreement.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Ductal carcinoma in situ (DCIS)
- National Cancer Institute — Breast cancer treatment (PDQ)
- Breast Cancer Now — DCIS treatment
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.